Skip to content
The Nexus
HEALTHJul 31 · 12:50 UTCQUARTZCris Tolomia

FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote

The FDA advisory panel supported Replimune's melanoma treatment RP1 in a 10-3 vote, increasing its chances of approval before the Aug. 2 deadline. RP1 is an engineered viral immunotherapy previously rejected by the FDA.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
FDA advisory panelorganizationReplimuneorganizationRP1topicmelanomatopicFDAorganization
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting

FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote · The Nexus